KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) Research & Development (2016 - 2025)

Novartis Ag's Research & Development history spans 14 years, with the latest figure at -$2.7 billion for Q2 2025.

  • On a quarterly basis, Research & Development fell 15.21% to -$2.7 billion in Q2 2025 year-over-year; TTM through Jun 2025 was -$14.8 billion, a 91.93% decrease, with the full-year FY2025 number at $11.2 billion, up 11.75% from a year prior.
  • Research & Development hit -$2.7 billion in Q2 2025 for Novartis Ag, up from -$4.8 billion in the prior quarter.
  • Over the last five years, Research & Development for NVS hit a ceiling of -$194.0 million in Q3 2022 and a floor of -$5.3 billion in Q2 2023.
  • Historically, Research & Development has averaged -$2.1 billion across 5 years, with a median of -$1.3 billion in 2021.
  • Biggest five-year swings in Research & Development: tumbled 2058.85% in 2023 and later surged 55.51% in 2024.
  • Tracing NVS's Research & Development over 5 years: stood at -$240.0 million in 2021, then rose by 5.83% to -$226.0 million in 2022, then tumbled by 2058.85% to -$4.9 billion in 2023, then rose by 1.87% to -$4.8 billion in 2024, then skyrocketed by 43.05% to -$2.7 billion in 2025.
  • Business Quant data shows Research & Development for NVS at -$2.7 billion in Q2 2025, -$4.8 billion in Q4 2024, and -$2.4 billion in Q2 2024.